当前位置: 首页 >> 检索结果
1501. A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosis.
作者: Christopher P Denton.;Otylia Kowal-Bielecka.;Susanna M Proudman.;Marzena Olesińska.;Margitta Worm.;Nicoletta Del Papa.;Marco Matucci-Cerinic.;Jana Radewonuk.;Jeanine Jochems.;Adrian Panaite.;Amgad Shebl.;Anna Krupa.;Yannick Allanore.;Jutta H Hofmann.;Maria J Gasior.
来源: Rheumatology (Oxford). 2025年64卷6期3657-3666页
The primary objective was the safety of s.c. immunoglobulin, IgPro20 (Hizentra, CSL Behring) in adults with dcSSc. Secondary objectives included pharmacokinetics and relative bioavailability of IgPro20, and safety and pharmacokinetics of IVIG, IgPro10 (Privigen, CSL Behring).
1502. Evaluation of patient-based disease activity score (PDAS) in the Japanese rheumatoid arthritis patient registry (NinJa registry).
作者: Hirofumi Shoda.;Toshihiro Matsui.;Shigeto Tohma.;Tetsuji Sawada.
来源: Rheumatology (Oxford). 2025年64卷6期3415-3425页
Patient-reported outcomes (PROs) should be regarded as an important factor in the management of rheumatic diseases. The patient-based disease activity score (PDAS) was developed as a clinically reliable composite measure for evaluating PROs in RA patients. To replicate and further characterize PDAS, we analysed PDAS and its clinical relevancy in the National Database of Rheumatic Diseases in Japan (NinJa).
1504. Comment on: Renal arteriosclerosis in kidney biopsies associated with higher 10-year atherosclerotic cardiovascular disease in lupus nephritis: Reply.
作者: Shivani Garg.;Brad Rovin.;Amish N Raval.;Christie M Bartels.
来源: Rheumatology (Oxford). 2025年64卷5期3200-3201页 1506. Faecal microbiota transplantation in patients with systemic sclerosis and lower gastrointestinal tract symptoms in Norway (ReSScue): a phase 2, randomised, double-blind, placebo-controlled trial.
作者: Håvard Fretheim.;Imon Barua.;Gunnstein Bakland.;Alvilde Dhainaut.;Anne-Kristine Halse.;Maylen N Carstens.;Henriette Didriksen.;Øyvind Midtvedt.;Knut E A Lundin.;Lars Aabakken.;Vikas K Sarna.;Hasse K Zaré.;Dinesh Khanna.;Oliver Distler.;Tore Midtvedt.;Espen S Bækkevold.;Inge C Olsen.;Diana Domanska.;Maiju E Pesonen.;Øyvind Molberg.;Anna-Maria Hoffmann-Vold.
来源: Lancet Rheumatol. 2025年7卷5期e323-e332页
Gastrointestinal tract involvement is highly prevalent in systemic sclerosis, with few treatment options. We assessed the efficacy and safety of faecal microbiota transplantation using standardised anaerobic cultivated human intestinal microbiome (ACHIM) as a novel treatment option for patients with systemic sclerosis and symptomatic lower gastrointestinal tract involvement.
1507. Teledidactic peer-tutored musculoskeletal ultrasound training for medical students-the TELMUS study.
作者: Ricarda Neubauer.;Florian Recker.;Claus-Juergen Bauer.;Simon Petzinna.;Pantelis Karakostas.;Charlotte Behning.;Valentin Sebastian Schäfer.
来源: Rheumatology (Oxford). 2025年64卷6期3344-3351页
Despite growing interest in musculoskeletal ultrasound (MSUS), training opportunities are often limited due to staff shortages and disbalances of expertise between rural and urban areas. Teledidactic approaches have the potential to expand access to training opportunities. This study aims to compare the effectiveness of teledidactic peer-tutored MSUS training to a conventional approach.
1508. Tacrolimus as first-line therapy in a US cohort of idiopathic inflammatory myopathies related interstitial lung disease.
作者: Kamaree J R Harris.;Erica A Ludtke.;Blaire Goldberg.;Natalie N McCall.;Justin C Hewlett.;Erin M Wilfong.
来源: Rheumatology (Oxford). 2025年64卷SI期SI179-SI183页
Calcineurin inhibitors are commonly used to treat idiopathic inflammatory myopathies related interstitial lung disease (IIM-ILD) in Asia but not in the USA. Here, we evaluate the efficacy of tacrolimus (TAC) as first-line immunosuppressive therapy in a US cohort of IIM-ILD.
1509. Association between large vessel vasculitis and inflammatory bowel disease: a case-control study.
作者: François Maillet.;Yann Nguyen.;Olivier Espitia.;Laurent Perard.;Carlo Salvarani.;Etienne Rivière.;Dieynaba Ndiaye.;Cécile-Audrey Durel.;Philippe Guilpain.;Luc Mouthon.;Anna Kernder.;Javier Loricera.;Pascal Cohen.;Isabelle Melki.;Claire de Moreuil.;Nicolas Limal.;Arsène Mékinian.;Nathalie Costedoat-Chalumeau.;Nathalie Morel.;Jonathan Boutemy.;Loïc Raffray.;Jean-Sébastien Allain.;Valérie Devauchelle.;Isabelle Kone-Paut.;Marc Fabre.;Marie Durel.;Antoine Dossier.;Sébastien Abad.;Marcella Visentini.;Adrien Bigot.;Halil Yildiz.;Olivier Fain.;Maxime Samson.;Guillaume Gondran.;Vered Abitbol.;Benjamin Terrier.
来源: Rheumatology (Oxford). 2025年64卷6期3724-3732页
To describe the characteristics and outcome of patients with the association of large vessel vasculitis (LVV, Takayasu arteritis [TA] or GCA) and IBD.
1512. Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study.
作者: Kathleen M M Vanni.;Kaitlin R McCarter.;Xiaosong Wang.;Caitlyn Duffy.;Jamie P Dela Cruz.;Holly Wobma.;Sarah Nikiforow.;Elena M Massarotti.;Karen H Costenbader.;Jessica S Little.;Ellen M Gravallese.;Gregory C McDermott.;Caron A Jacobson.;Jeffrey A Sparks.
来源: Lancet Rheumatol. 2025年7卷4期e226-e229页 1514. Incidence of ANCA-associated vasculitis and polyarteritis nodosa in Norfolk, UK, from 2011 to 2020.
作者: Sarah Fordham.;Karen Ashurst.;Alice Bartoletti.;Fiona L Coath.;Georgina Ducker.;Ajay Kamath.;Warda Mushtaq.;Hassan Naeem.;Isabelle Nicholls.;Claire Sheehy.;Katherine Sisson.;Richard Watts.;Chetan B Mukhtyar.
来源: Rheumatology (Oxford). 2025年64卷6期3718-3723页
The aim of this study was to report the annual and age-specific incidence of AAV and PAN in the adult population of Norfolk County, UK.
1515. Plasma proteomics for risk prediction and identification of novel drug targets in systemic lupus erythematosus.
作者: Sisi Yang.;Yuanyuan Zhang.;Ziliang Ye.;Yanjun Zhang.;Xiaoqin Gan.;Yu Huang.;Hao Xiang.;Yiting Wu.;Yiwei Zhang.;Xianhui Qin.
来源: Rheumatology (Oxford). 2025年64卷6期4032-4040页
The relationship between proteomic profiles and incident systemic lupus erythematosus (SLE) remains unclear. We aimed to identify candidate plasma proteins for SLE risk in women, discover potential treatment targets for SLE and develop and validate a protein-based prediction model for SLE risk.
1519. A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis.
作者: Hilde Jenssen Bjørkekjær.;Cosimo Bruni.;Kaspar Broch.;Cathrine Brunborg.;Patricia E Carreira.;Paolo Airò.;Carmen Pilar Simeón-Aznar.;Marie-Elise Truchetet.;Alessandro Giollo.;Alexandra Balbir-Gurman.;Mickael Martin.;Christopher P Denton.;Armando Gabrielli.;Francesco Del Galdo.;Madelon C Vonk.;Håvard Fretheim.;Helle Bitter.;Øyvind Midtvedt.;Arne Andreassen.;Sverre Høie.;Yoshiya Tanaka.;Gabriela Riemekasten.;Ulf Müller-Ladner.;Marco Matucci-Cerinic.;Ivan Castellví.;Elise Siegert.;Eric Hachulla.;Øyvind Molberg.;Oliver Distler.;Anna-Maria Hoffmann-Vold.; .
来源: Rheumatology (Oxford). 2025年64卷6期3643-3656页
The 2022 European Society of Cardiology and European Respiratory Society (ESC/ERS) guidelines for pulmonary arterial hypertension (PAH) recommend risk stratification to optimize management. However, the performance of generic PAH risk stratification tools in patients with SSc-associated PAH remains unclear. Our objective was to identify the most accurate approach for risk stratification at SSc-PAH diagnosis.
1520. Performance of spondyloarthritis-specific health utilities based on the ASAS Health Index: an ancillary analysis from the ASAS-HI validation study.
作者: Omar-Javier Calixto.;Uta Kiltz.;Wilson Bautista-Molano.;Annelies Boonen.;Sander van Kuijk.;Ivette Essers.;Désirée van der Heijde.;Juergen Braun.;Xenofon Baraliakos.
来源: Rheumatology (Oxford). 2025年64卷6期3526-3533页
To compare the Spondyloarthritis (SpA)-specific universal utility estimation from ASAS Health Index (U-ASAS-HI) with generic utilities and to understand the contribution of health outcomes, personal- and country-level factors to the U-ASAS-HI.
|